Document is current

Article History

Received: 31 October 2023

Revised: 15 December 2023

Accepted: 16 December 2023

First Online: 9 February 2024

Declarations

:

: The authors have no conflict of interest for this study. Financial disclosures for the previous 12 months: Raquel Barbosa, Anne Sophie Rolland, Amaury De Barros, Paulo Bastos, Ana Marques, Lucie Hopes, Isabelle Benatru, Dominique Guehl, David Maltete, Cecile Hubsch, and Bechir Jarraya report no disclosures. Caroline Moreau has received consultation fees from Boston Sci, Orkyn, Feet me Health, scientific 4 grants from ANR, France Parkinson, Vaincre Parkinson, and equities from IN brain Pharma, 5 INvenis biotehrapie Christine Brefel-Courbon has received research grant from Association France Parkinson, and fees for lectures and consultancies from Aguettant, Orkyn, NHC, Zambon and AbbVie. Olivier Rascol has acted as a scientific advisor for drug companies developing antiparkinsonian medications (Abbott, Abbvie, Acorda, Adamas, BIAL, Biogen, Boehringer-Ingelheim, Cynapsus, GSK, Impax, Merck, Osmotica, Oxford-Biomedica, Lundbeck, Novartis, Prexton, Servier, Sunovion, TEVA, UCB, and Zambon). Fabienne Ory-Magne has received honoraria for serving as an advisory board member from Abbvie, Medtronic, Orphalan, Aguettant, and Orkyn, and for consultancy activities from Aguettant, Abbvie, Orphalan, Ellivie, Homeperf, and Orkyn. Elodie Hainque has acted as scientific advisory boards for Medtronic and Boston Scientific and received speech honorarium from Medtronic and Boston Scientific. Tiphaine Rouaud has received honoraria from Medtronic, Abbvie, Elivie, Homeperf, Orkyn, Asdia et Novartis. Alexandre Eusebio has received research support from ANR, DGOS, and France Parkinson charity; honoraria from Abbvie, Medtronic and Boston Scientific, and travel grants from Homeperf. Sophie Drapier has received honoraria from Medtronic and Boston Christine Tranchan has received consultation fees from Abbvie and Linde, therapeutic studies with Roche, and participation to a meeting with Ipsen. Thomas Wirth received grants from the Revue Neurologique, the France Parkinson Organization, the Fondation Planiol, and the APTES organizations, honoraria from IPSEN, Abbvie and Edimark, travel fundings from LVL medical, Abbvie and the Movement Disorders Society. Caroline Giordana, Honoraria to speak from AbbVie and Abbott. Melissa Tir reports honoraria and consultation fees from Boston Scientific, Medtronic, Adelia, Elivie, Aguettant. Stephane Thobois, Honoraria to speak from, consultancies and advisory board from: Abbvie, Orion, Merz, Medtronic, Boston. Jean Christophe Corvol has served in advisory boards for Alzprotect, Bayer, Biogen, Idorsia, Prevail Therapeutic, Servier, Theranexus, UCB; and received grants from Sanofi and the Michael J Fox Foundation. Matthieu Bereau reports grants from France Parkinson Foundation, reimbursement of travel expenses to scientific meetings from Asten, Boston Scientific, Elivie and Medtronic, honoraria from AbbVie, Aguettan, Allergan, Asdia and Merz Pharma for lecturing outside the submitted work. David Devos has received PHRC grants from the French Ministry of Health (PHRC & ANR), European grants (H2020 and Coen), and research funding from the ARSLA charity, France Parkinson charity, Fondation Credit Agricole, Fondation de France. He served on advisory boards, served as a consultant, and given lectures for pharmaceutical companies such as Abbvie, Alterity, Orkyn, Air Liquide, Elivie, Home perf, Apopharma, Lundbeck, Everpharma, Medtronic, Boston Scientific, Ever pharma, Boston Scientific, UCB pharma, EISAI, Servier, PTC Therapeutics, Orion, AB science, Alzprotect, and Cajal Neuroscience. Cure Parkinson Trust. He holds stakes in InBrain Pharma and Invenis biotherapies. Margherita Fabbri received Honoraria to speak from AbbVie, ORKYN, and BIAL, consultancies from BIAL and LVL Medical; Grant from France Parkinson, HORIZON 2022 and MSA Coalition.

: This study was approved by CPP (Comité de Protection des Personnes) Nord Ouest-IV Ethical Committee and registered on the ClinicalTrials.gov website (NCT02360683). Patients have given written informed consent, the study has been conducted according to good clinical practice and local regulations, and data collection was compliant with all General Data Protection Regulation (GDPR) rules.